Moderna has secured FDA approval for its respiratory syncytial virus (RSV ... and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized ... In a earnings report Tuesday, Pfizer said sales of its vaccine Abrysvo fell 62% year over year ...

On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered ...

Pfizer Inc. (NYSE:PFE – Get Free Report ... infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 ...

However, sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, Abrysvo declined in the quarter. Pfizer's COVID revenues include direct sales and alliance revenues from its ...

That shot, Abrysvo, brought in $198 million in the quarter, missing expectations by more than $300 million. Pfizer’s RSV vaccine has struggled to compete with one from GSK in a market that now ...